Denosumab Delays Linked to Fracture Risk in Aged Care
A new study of over 10,600 Australian aged care residents reveals significant gaps in osteoporosis medication management, with delays and missed follow-up treatments posing serious health risks.
The Study
A recent analysis published in the British Journal of Clinical Pharmacology examined medication administration data from Australian residential aged care facilities between 2018 and 2022.
Key Findings
The research uncovered two critical issues regarding the osteoporosis drug denosumab:
-
Widespread Delays: 20% of residents prescribed denosumab experienced doses delayed beyond the recommended six-month interval. Even a delay of just 30 days can lead to vertebral fractures due to rapid bone resorption.
-
Lack of Follow-On Therapy: More than 98% of residents who stopped denosumab treatment did not receive follow-on bisphosphonate therapy as recommended by clinical guidelines.
"Missed or delayed doses can lead to vertebral fractures due to rapid bone resorption, even with delays as short as 30 days."
Root Cause
The researchers attributed the problem not to the medication itself, but to health system coordination issues. The findings suggest systemic failures in managing scheduled treatments and transitions between therapies in residential aged care settings.
Bottom Line
For residents on denosumab, strict adherence to the six-month dosing schedule is critical. When treatment is stopped, immediate initiation of alternate therapy is necessary to prevent dangerous bone loss and fractures.